Search Results - cancer%2foncology

90 Results

Sort By:

Dual-Action Inhibition Strategy for KRAS and LKB1 Mutant NSCLC

NU 2023-113 INVENTORS Lillian Eichner (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* Reuben Shaw (Salk Institute) SHORT DESCRIPTION A dual drug combination to target KRAS and LKB1 mutant non–small cell lung cancer that results in superior efficacy by enhancing T cell recruitment and reducing tumor burden. BACKGROUND Lung...

Published: 4/29/2026 | Updated: 4/29/2026 | Inventor(s): Reuben Shaw

Keywords(s): Cancer/Oncology, Lung cancer, Repurposed Drugs, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics.

NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036) INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* SHORT DESCRIPTION MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders. BACKGROUND Leukemia and brain...

Published: 4/30/2026 | Updated: 4/29/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 COMPASS mutant cancer

NU 2022-053 INVENTORS Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* SHORT DESCRIPTION A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...

Published: 4/29/2026 | Updated: 4/29/2026 | Inventor(s):

Keywords(s): Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment

SHORT DESCRIPTION Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma. INVENTORS Amy Heimberger* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery * Principal Investigator NU 2025-212 IP...

Published: 4/29/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics

Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools

Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets

SHORT DESCRIPTION A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets. INVENTORS Shana Kelley* Weinberg College of Arts & Sciences, Department of Chemistry Yi Li * Principal Investigator NU 2025-050 IP STATUS PCT...

Published: 4/27/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools

Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms

SHORT DESCRIPTION Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs). NU Tech IDs: NU 2018-169, NU 2021-005 PRINCIPAL INVESTIGATOR Peng Ji Northwestern University Feinberg School of Medicine, Department of Pathology IP...

Published: 4/16/2026 | Updated: 4/16/2026 | Inventor(s):

Keywords(s): Breast cancer, Cancer/Oncology, Colon cancer, Leukemia, Lung cancer, Pancreatic cancer, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

Nano-therapeutics Targeting Cholesterol Efflux Transporter in Macrophages for Cancer Immunotherapy

NU 2025-160 INVENTORS Jason Miska* Feinberg School of Medicine, Department of Neurological Surgery Peng Zhang* Feinberg School of Medicine, Department of Neurological Surgery SHORT DESCRIPTION Novel nanoparticle technology that modulates macrophage cholesterol metabolism to boost anti-tumor immunity in GBM. BACKGROUND Glioblastoma...

Published: 4/16/2026 | Updated: 4/14/2026 | Inventor(s):

Keywords(s): Adjunct therapy, Brain cancer, Cancer/Oncology, CNS - Central Nervous System, Drug delivery, Immunotherapy, Nanoparticle, Neurologic disease, Therapeutics

Category(s): Life Sciences > Therapeutics

SEC61 Complex as a Novel Therapeutic Target to Enhance Immunotherapy Response in Glioblastoma

NU 2023-011 INVENTORS Irina Balyasnikova* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery Joseph Duffy SHORT DESCRIPTION A targeted therapeutic approach that inhibits the SEC61 complex to enhance responses to immunotherapy in glioblastoma. BACKGROUND Glioblastoma (GBM) is the most aggressive primary...

Published: 4/14/2026 | Updated: 4/14/2026 | Inventor(s):

Keywords(s): Brain cancer, Cancer/Oncology, Immunotherapy, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Anti-TYRP1 Bi-specific T cell Engager for Treatment of TYRP1-expressing melanoma

NU 2022-123 INVENTORS Irina Balyasnikova (Feinberg School of Medicine, Department of Neurological Surgery)* Isabelle Le Poole (Feinberg School of Medicine, Department of Dermatology)* SHORT DESCRIPTION A bispecific T cell engager that targets CD3+ T cells and TYRP1-expressing melanoma cells. BACKGROUND Melanoma is the deadliest form of skin...

Published: 4/14/2026 | Updated: 4/14/2026 | Inventor(s):

Keywords(s): Biologic, Cancer/Oncology, Immunotherapy, Melanoma, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Bi-specific Lipid Nanoparticles for Boosting Antitumor Immunity in Glioblastoma

SHORT DESCRIPTION A bispecific lipid nanoparticle that bridges tumor-associated myeloid cells (TAMCs) and glioma cells by dual checkpoint blockade and simultaneously reprograms TAMCs into antitumor effectors via targeted delivery of a STING agonist. INVENTORS Maciej Lesniak* Northwestern University Feinberg School of Medicine,...

Published: 4/30/2026 | Updated: 4/14/2026 | Inventor(s):

Keywords(s): Brain cancer, Cancer/Oncology, Drug delivery, Immunotherapy, Nanoparticle, Nanotechnology, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

1 2 3 4 5 6 7 8 9